Caricamento...
Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
BACKGROUND: In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significantly improved progression‐free survival (PFS) versus placebo plus fulvestrant in patients with hormone receptor‐positive (HR+), HER2‐negative advanced breast cancer (ABC). This study assessed patient‐re...
Salvato in:
| Pubblicato in: | Oncologist |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7011625/ https://ncbi.nlm.nih.gov/pubmed/32043763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0551 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|